naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone · 1-pentyl-3-(1-naphthoyl)indole · MW 341.45 g/mol · C₂₄H₂₃NO · CAS 209414-07-3 · ChEMBL561013
John W. Huffman's compound #018. A naphthoylindole synthetic cannabinoid receptor agonist (SCRA) — the original active ingredient behind "Spice" and "K2". Structurally nothing like Δ⁹-THC (no classical tricyclic terpenoid core), yet it hits the same CB1 receptor harder and, decisively, as a high-efficacy FULL agonist with no ceiling. That single pharmacological fact — not chemistry, not scheduling — is why it maims and kills where cannabis does not. Context names: Spice, K2, "fake weed", synthetic marijuana, "legal high".
JWH-018 engages the exact same target as THC — the CB1 receptor, a Gi/o-coupled GPCR and the densest GPCR in the brain (basal ganglia, hippocampus, cerebellum, cortex). The pharmacology diverges on the one axis that matters clinically: intrinsic efficacy. THC is a low-efficacy partial agonist; JWH-018 is a high-efficacy full agonist. It also binds tighter (CB1 Ki ≈ 9 nM vs THC ≈ 40 nM). Higher affinity plus maximal efficacy removes the soft ceiling that makes cannabis self-limiting.
JWH-018 is a naphthoylindole: an indole core, an N-pentyl chain, and a 1-naphthoyl group linked by a ketone bridge. It carries none of THC's terpenoid tricyclic scaffold, yet its lipophilic arms fill the same lateral orthosteric pocket of CB1 and drive the Trp3566.48 "toggle twin" switch fully open.
Unlike THC's submaximal activation, JWH-018 produces maximal Gi/o activation, robust β-arrestin recruitment and rapid CB1 internalization in functional assays (Atwood et al., 2010). It behaves like the reference full agonists CP-55940 / WIN-55212-2 — not like the plant drug it is sold to imitate.
Active CB1 inhibits adenylyl cyclase, closes N/P/Q-type voltage-gated Ca²⁺ channels and opens GIRK K⁺ channels. With a full agonist these effects run to completion across every CB1-bearing terminal at once — profound, un-titratable synaptic suppression.
CB1 is sparse in brainstem respiratory nuclei, so death is not by opioid-style apnea. Instead, runaway full agonism drives seizures, excitotoxicity, hyperthermia, tachyarrhythmia and cardiovascular collapse — a toxidrome cannabis simply cannot produce.
This is a crucial, under-appreciated hazard: several phase-I hydroxylated metabolites of JWH-018 remain CB1 agonists in their own right (unlike THC-COOH, which is inert). Metabolism does not reliably switch the drug off — it can extend and layer the intoxication.
JWH-018 is also a high-affinity CB2 full agonist (Ki ≈ 2.9 nM, immune/microglial), with essentially no opioid, µ/δ/κ activity (Ki > 10 µM). It is a clean, potent cannabinoid — which is exactly the problem.
The takeaway is efficacy, not affinity or scaffold. Two molecules can share a receptor and a Ki in the same order of magnitude yet belong to different danger classes. THC's partiality gives it a self-limiting plateau; JWH-018's full agonism erases that plateau. "It binds CB1 like weed does" is true and lethally misleading.
JWH-018 is a highly lipophilic solid (logP ≈ 6.2) almost always consumed by smoking plant matter that has been sprayed with a solution of the drug. This delivery route is the first hazard: spraying is inhomogeneous, so one pinch of a "Spice" blend can contain a trivial dose and the next pinch a many-fold overdose from the same bag. There is no standardization, no dose printed on anything, and the active mass per gram of herb varies wildly batch to batch and even within a single batch.
Absorbed drug is oxidized hepatically — CYP2C9, CYP1A2 and CYP3A4 generate monohydroxylated (indole, alkyl-chain and naphthalene positions) and carboxylated metabolites, which are then glucuronidated for urinary excretion. Human PK parameters are poorly characterized (no clinical dosing studies exist), but the pharmacology is dominated by two facts below.
Metabolism cascade: hydroxylation precedes carboxylation and glucuronidation — but, unlike THC, the first-generation hydroxy metabolites are not pharmacologically silent.
The active-metabolite trap (★): monohydroxylated JWH-018 metabolites retain measurable CB1 agonist activity (Brents et al., 2011, Chem Res Toxicol). Where THC's terminal metabolite (THC-COOH) is inert, JWH-018's metabolic pathway can prolong and compound the effect — a pharmacokinetic reason spice intoxications run longer and less predictably than a comparable cannabis episode.
Detection: because the scaffold is unrelated to THC, JWH-018 and its metabolites are invisible to standard cannabinoid (THC-COOH) immunoassays. This "beats-the-drug-test" property drove much of the early demand and means users, ER staff and coroners can all miss it without targeted LC-MS/MS for the specific analog.
Because CB1 sits presynaptically on nearly every neuron class, a full agonist does not produce a stronger version of a cannabis high — it produces a qualitatively different, systemic toxidrome. Emergency presentations and published fatality series describe a picture with almost no overlap with the benign cannabis ceiling.
Generalized tonic-clonic seizures, status epilepticus, severe agitation and acute psychosis (paranoia, hallucinations, catatonia) are hallmark and dose-unpredictable. Full CB1 agonism disrupts the excitation/inhibition balance far beyond THC's mild disinhibition — spice psychosis can be prolonged and require antipsychotics/benzodiazepines. "Zombie"-outbreak clusters (e.g. AMB-FUBINACA, NYC 2016) are the same drug class.
Marked tachycardia, hypertension, chest pain, QT changes, supraventricular and ventricular arrhythmias, and reports of myocardial infarction in young users with clean coronaries. The cardiotoxicity is disproportionate to the "just weed" expectation and is a leading cause of spice-associated collapse.
Clusters of acute kidney injury (AKI, sometimes requiring dialysis) are documented with several synthetic cannabinoids, alongside hyperthermia, rhabdomyolysis, hyperemesis, hyperkalaemia and metabolic acidosis. None of these are features of THC toxicity.
Heavy use produces a genuine dependence and a severe withdrawal syndrome (agitation, tachycardia, vomiting, insomnia) worse than cannabis withdrawal. Unlike THC, JWH-018 and its successor synthetic cannabinoids have a documented body count — direct toxicity and deaths are reported in the toxicology literature and by the EMCDDA/DEA.
The mechanistic through-line, again, is the missing ceiling. THC's low intrinsic efficacy caps its effect; JWH-018's full efficacy does not — so overdose is not "too high", it is a multi-organ emergency.
Evidence-based, non-moralistic. The single most dangerous thing about JWH-018 is the belief that it is "just fake weed." It is not weed. It is a high-efficacy full agonist with no established safe dose, sold on unlabeled, unevenly-sprayed plant matter.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
CB1
Cannabinoid receptor 1 (CNR1)
|
Ki ≈ 9 nM
human range 2.0–9.5 nM
|
FULL agonist | |
|
CB2
Cannabinoid receptor 2 (CNR2)
|
Ki ≈ 2.9 nM
human range 2.9–9.6 nM
|
FULL agonist | |
|
CB1-OHmet
Hydroxy metabolites (active)
|
retains CB1 activity
Brents 2011
|
Agonist | |
|
µ / δ / κ OR
Opioid receptors
|
Ki > 10,000 nM
no opioid activity
|
Inactive | |
|
Δ9-THC ref.
for contrast (partial)
|
Ki ≈ 40 nM
low efficacy
|
Partial agonist |
Binding of a greasy, near-desolvated cannabinoid into CB1's lipid-facing groove is driven by the hydrophobic effect: burying the naphthoylindole surface releases ordered water, a favorable solvent-entropy gain (positive ΔSsolv) that pays for a pocket with few polar contacts — hence single-digit-nM affinity from a flexible molecule.
Efficacy lives on the receptor's side of the ledger. Agonist engagement collapses the CB1 conformational microstate distribution toward the active, transducer-coupled ensemble — a negative ΔSconf the FlexAID∆S tENCoM term reads as vibrational-mode rigidification on binding.
Partial vs full agonism is the depth of that collapse. THC only partially narrows the ensemble: residual conformational entropy is retained, the receptor keeps sampling inactive-leaning states, and the output is submaximal efficacy with a soft ceiling. JWH-018 drives a deeper Shannon-entropy collapse — a tighter, more fully ordered active state and stronger Gi/o/β-arrestin coupling with no residual "off" states to fall back into. Same pocket, same order-of-magnitude Ki — but the fuller entropy collapse is the molecular reason the ceiling, and the safety, disappear.